AI method lowers radiation dose, speeds scanning times

An artificial intelligence (AI) technique developed at Massachusetts General...Read more on AuntMinnie.comRelated Reading: AI advances MRI for prostate cancer patients Is artificial intelligence ethical in healthcare? Deep learning may produce sharp reductions in DBT dose AI can help distinguish lung nodules on CT scans Can AI help in the fight against gadolinium deposition?
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news

Related Links:

Publication date: 18 October 2018Source: Cell, Volume 175, Issue 3Author(s): David A. Quigley, Ha X. Dang, Shuang G. Zhao, Paul Lloyd, Rahul Aggarwal, Joshi J. Alumkal, Adam Foye, Vishal Kothari, Marc D. Perry, Adina M. Bailey, Denise Playdle, Travis J. Barnard, Li Zhang, Jin Zhang, Jack F. Youngren, Marcin P. Cieslik, Abhijit Parolia, Tomasz M. Beer, George Thomas, Kim N. Chi
Source: Cell - Category: Cytology Source Type: research
The provision of hormone therapy, both estrogens and antiandrogens, to adult transgender females is well within the scope of practice of the obstetrician gynecologist. The goal is to induce feminizing changes and suppress previously developed masculinization. Estrogens in sufficient doses will usually achieve both goals with augmentation by antiandrogens. The primary short-term risk of estrogens is thrombosis, but long-term risk in transgender females is unclear. Optimal care requires pretreatment education and assessment, individualized dosing, ongoing routine monitoring, and standard breast and prostate cancer screening.
Source: Clinical Obstetrics and Gynecology - Category: OBGYN Tags: Caring for Lesbians, Bisexual Women, Transgender, and Gender Nonconforming People Source Type: research
BJU International, EarlyView.
Source: BJU International - Category: Urology & Nephrology Authors: Source Type: research
Source: BMJ Comments - Category: General Medicine Source Type: forums
Condition:   Prostate Cancer Intervention:   Drug: Chitosan Sponsor:   Medical University of South Carolina Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Metastatic Castration-Resistant Prostate Cancer (mCRPC) With Homologous Recombination Deficiency (HRD) Intervention:   Drug: Pamiparib 60 mg PO BID Sponsor:   BeiGene Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Prostate Cancer Intervention:   Drug: Chitosan Sponsor:   Medical University of South Carolina Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Metastatic Castration-Resistant Prostate Cancer (mCRPC) With Homologous Recombination Deficiency (HRD) Intervention:   Drug: Pamiparib 60 mg PO BID Sponsor:   BeiGene Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
PROSTATE cancer symptoms can go undetected in the early stages, but when signs do begin to appear what can you do to test if you have the disease?
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
PROSTATE cancer symptoms can go undetected in the early stages, but when signs do begin to appear what can you do to test if you have the disease?
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
More News: Cancer | Cancer & Oncology | CT Scan | Learning | Lung Transplant | Medical Ethics | PET Scan | Prostate Cancer | Radiology | Universities & Medical Training